JP2011177182A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011177182A5 JP2011177182A5 JP2011083991A JP2011083991A JP2011177182A5 JP 2011177182 A5 JP2011177182 A5 JP 2011177182A5 JP 2011083991 A JP2011083991 A JP 2011083991A JP 2011083991 A JP2011083991 A JP 2011083991A JP 2011177182 A5 JP2011177182 A5 JP 2011177182A5
- Authority
- JP
- Japan
- Prior art keywords
- pla2
- sample
- individual
- activity
- vascular disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 claims 11
- 230000000694 effects Effects 0.000 claims 9
- 208000019553 vascular disease Diseases 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 2
- -1 4-nitrophenylsuccinyl Chemical group 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 102100037611 Lysophospholipase Human genes 0.000 claims 1
- 108010058864 Phospholipases A2 Proteins 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54158304P | 2004-02-03 | 2004-02-03 | |
| US60/541,583 | 2004-02-03 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006552204A Division JP5155564B2 (ja) | 2004-02-03 | 2005-02-03 | Ｌｐ−ＰＬＡ２活性を検出する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011177182A JP2011177182A (ja) | 2011-09-15 |
| JP2011177182A5 true JP2011177182A5 (enExample) | 2013-03-14 |
Family
ID=34837507
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006552204A Expired - Fee Related JP5155564B2 (ja) | 2004-02-03 | 2005-02-03 | Ｌｐ−ＰＬＡ２活性を検出する方法 |
| JP2011083991A Ceased JP2011177182A (ja) | 2004-02-03 | 2011-04-05 | Ｌｐ−ＰＬＡ２活性を検出する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006552204A Expired - Fee Related JP5155564B2 (ja) | 2004-02-03 | 2005-02-03 | Ｌｐ−ＰＬＡ２活性を検出する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20070281323A1 (enExample) |
| EP (2) | EP2280282A1 (enExample) |
| JP (2) | JP5155564B2 (enExample) |
| DK (1) | DK1718967T3 (enExample) |
| ES (1) | ES2416344T3 (enExample) |
| WO (1) | WO2005074604A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004026439D1 (de) | 2003-05-28 | 2010-05-20 | Glaxo Group Ltd | Lp-pla2-aktivitätstest mit hohem durchsatz |
| US20070166777A1 (en) * | 2004-04-16 | 2007-07-19 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
| US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
| EP2313778B1 (en) * | 2008-07-18 | 2015-01-28 | Boston Medical Center Corporation | Diagnostics for membranous nephropathy |
| EP2246440A1 (en) * | 2009-04-29 | 2010-11-03 | Aterovax | Enzymatic assay for the quantitative determination of phospholipase a1 or a2 activity in a sample |
| WO2012003475A1 (en) * | 2010-07-02 | 2012-01-05 | Bg Medicine, Inc. | Statin therapy monitored by galectin- 3 measurement |
| CN102692507B (zh) * | 2011-07-29 | 2015-09-16 | 南京诺尔曼生物技术有限公司 | 脂蛋白相关磷脂酶a2(lppla2)测定试剂盒(胶乳增强免疫比浊法) |
| CN103048457B (zh) * | 2012-11-27 | 2014-12-17 | 同昕生物技术（北京）有限公司 | 心肌梗死预警胶体金试剂盒及其制备方法 |
| US20140283157A1 (en) * | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
| CN104237517B (zh) * | 2013-06-18 | 2016-05-18 | 深圳市安群生物工程有限公司 | 检测人Lp-PLA2蛋白的荧光免疫层析试纸及其制备方法 |
| US20150086998A1 (en) * | 2013-09-24 | 2015-03-26 | Thomas D. Schaal | Value-assigned solutions of lipoprotein-associated phospholipase a2 having a long shelf-life |
| CN103792353B (zh) * | 2013-10-17 | 2015-07-15 | 武汉生之源生物科技有限公司 | 一种脂蛋白相关磷脂酶a2含量检测试剂盒及其制备方法 |
| WO2015058158A1 (en) * | 2013-10-18 | 2015-04-23 | Diadexus, Inc. | METHOD FOR DETECTION OF LIPOPROTEIN-SPECIFIC Lp-PLA2 ASSOCIATION |
| CN104634970B (zh) * | 2015-02-10 | 2017-04-05 | 深圳市新产业生物医学工程股份有限公司 | 用于检测脂蛋白相关磷脂酶a2的试剂盒及其制备和应用 |
| WO2016127319A1 (zh) | 2015-02-10 | 2016-08-18 | 深圳市新产业生物医学工程股份有限公司 | 用于检测脂蛋白相关磷脂酶a2的试剂盒及其制备和应用 |
| CN104820097A (zh) * | 2015-05-22 | 2015-08-05 | 北京协和洛克生物技术有限责任公司 | 一种定量检测样本中脂蛋白磷脂酶a2浓度的液态芯片试剂盒及其制备方法 |
| US11237167B2 (en) * | 2017-01-24 | 2022-02-01 | Cleveland Heartlab, Inc. | Lp-PLA2 assays and composition with detergent |
| CN109917131B (zh) * | 2019-03-26 | 2021-12-17 | 苏州博源医疗科技有限公司 | 一种脂蛋白磷脂酶a2检测试剂及其制备和使用方法 |
| CN111175242A (zh) * | 2020-03-17 | 2020-05-19 | 湖南新大陆生物技术有限公司 | 一种脂蛋白磷脂酶a2检测试剂盒及其应用 |
| CN111662387A (zh) * | 2020-07-14 | 2020-09-15 | 重庆中元汇吉生物技术有限公司 | 抗人脂蛋白相关磷脂酶a2单克隆抗体及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4925788A (en) | 1986-10-24 | 1990-05-15 | Immunicon Corporation | Immunoassay system and procedure based on precipitin-like interaction between immune complex and Clq or other non-immunospecific factor |
| US5108933A (en) | 1988-09-16 | 1992-04-28 | Immunicon Corporation | Manipulation of colloids for facilitating magnetic separations |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| US5186827A (en) | 1991-03-25 | 1993-02-16 | Immunicon Corporation | Apparatus for magnetic separation featuring external magnetic means |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| EP0590327B1 (en) | 1992-09-11 | 2003-04-09 | F. Hoffmann-La Roche Ag | Detection of nucleic acids in blood |
| AU670108B2 (en) * | 1992-09-11 | 1996-07-04 | Becton Dickinson & Company | Improved antibodies to plasmodium falciparum |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US5981252A (en) | 1993-06-25 | 1999-11-09 | Smithkline Beecham | Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy |
| US5977308A (en) | 1993-10-06 | 1999-11-02 | Icos Corporation | Platelet-activating factor acetylhydrolase |
| DE69434609T2 (de) | 1993-10-06 | 2006-09-21 | Icos Corp., Bothell | Acethylhydrolase des Plättchen aktivierenden Faktors |
| US5847088A (en) | 1993-10-06 | 1998-12-08 | Icos Corporation | Antibodies specific for platelet-activating factor acetylhydrolase |
| US5656431A (en) | 1993-10-06 | 1997-08-12 | Icos Corporation | Platelet-activating factor acetylhydrolase |
| US6156504A (en) | 1996-03-15 | 2000-12-05 | The Penn State Research Foundation | Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays |
| US6630301B1 (en) | 1997-03-14 | 2003-10-07 | The Penn State Research Foundation | Detection of extracellular tumor-associated nucleic acid in blood plasma or serum |
| US6013256A (en) | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
| EP1057024A4 (en) * | 1998-02-23 | 2002-10-30 | Diadexus Inc | METHOD FOR USING PLA 2? AS A METASTASE MARKER AND ASU-SELECTED CARCINOMAS FOR DIAGNOSIS |
| WO2000024910A1 (en) | 1998-10-28 | 2000-05-04 | Smithkline Beecham Plc | Process of purification of low density lipoprotein associated phospholipase a2 using immobilized metal affinity chromatography |
| EP1133523A1 (en) | 1998-11-16 | 2001-09-19 | Genway Biotech, Inc. | Generation of antibodies using polynucleotide vaccination in avian species |
| JP4220603B2 (ja) | 1998-12-02 | 2009-02-04 | アルフレッサファーマ株式会社 | 血小板活性化因子アセチルヒドロラーゼ活性の測定方法 |
| WO2000047998A1 (en) | 1999-02-10 | 2000-08-17 | Cell Works Inc. | Class characterization of circulating cancer cells isolated from body fluids and methods of use |
| JP2002051164A (ja) * | 2000-05-24 | 2002-02-15 | Victor Co Of Japan Ltd | 音声コンテンツ試聴システム及びシステムサーバ並びに携帯電話機 |
| DE50102625D1 (de) | 2001-12-07 | 2004-07-22 | Sirs Lab Gmbh | Verbindungen zur Bestimmung der Aktivität von Phospholipase A2 |
| DE602004026439D1 (de) | 2003-05-28 | 2010-05-20 | Glaxo Group Ltd | Lp-pla2-aktivitätstest mit hohem durchsatz |
-
2005
- 2005-02-03 DK DK05712595.7T patent/DK1718967T3/da active
- 2005-02-03 JP JP2006552204A patent/JP5155564B2/ja not_active Expired - Fee Related
- 2005-02-03 EP EP10185947A patent/EP2280282A1/en not_active Withdrawn
- 2005-02-03 ES ES05712595T patent/ES2416344T3/es not_active Expired - Lifetime
- 2005-02-03 US US10/588,339 patent/US20070281323A1/en not_active Abandoned
- 2005-02-03 EP EP05712595.7A patent/EP1718967B1/en not_active Expired - Lifetime
- 2005-02-03 WO PCT/US2005/003211 patent/WO2005074604A2/en not_active Ceased
-
2011
- 2011-04-05 JP JP2011083991A patent/JP2011177182A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011177182A5 (enExample) | ||
| Zhu et al. | High level of neutrophil extracellular traps correlates with poor prognosis of severe influenza A infection | |
| US20230158491A1 (en) | Methods and compositions for detecting analytes | |
| Russell et al. | Biosensors for managing the COVID-19 cytokine storm: challenges ahead | |
| Hu et al. | The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies | |
| Aghamirza Moghim Aliabadi et al. | COVID‐19: A systematic review and update on prevention, diagnosis, and treatment | |
| Wang et al. | A meta-analysis of dysregulated miRNAs in coronary heart disease | |
| JP2016513094A5 (enExample) | ||
| Hallstrand et al. | Relationship between levels of secreted phospholipase A2 groups IIA and X in the airways and asthma severity | |
| JP2016511823A5 (enExample) | ||
| Van den Bergh et al. | Transcriptome analysis of monocyte-HIV interactions | |
| JP2014012007A5 (enExample) | ||
| JP2017505897A5 (enExample) | ||
| Yang et al. | Application of omics technology to combat the COVID‐19 pandemic | |
| Kagota et al. | Perivascular adipose tissue-enhanced vasodilation in metabolic syndrome rats by apelin and N-acetyl–l-cysteine-sensitive factor (s) | |
| JP2017500584A5 (enExample) | ||
| JP2007508527A5 (enExample) | ||
| Auld et al. | Pathogenesis of post-tuberculosis lung disease: defining knowledge gaps and research priorities at the second international post-tuberculosis symposium | |
| Rahe-Meyer et al. | An evaluation of cyclooxygenase-1 inhibition before coronary artery surgery: aggregometry versus patient self-reporting | |
| JP2015505371A5 (enExample) | ||
| Xu et al. | PROTAC based STING degrader attenuates acute colitis by inhibiting macrophage M1 polarization and intestinal epithelial cells pyroptosis mediated by STING-NLRP3 axis | |
| Nagatsuka et al. | Cardiovascular events occur independently of high on-aspirin platelet reactivity and residual COX-1 activity in stable cardiovascular patients | |
| Kojima et al. | Different profiles of Ca2+ responses to endothelin‐1 and PDGF in liver myofibroblasts during the process of cell differentiation | |
| Ribeiro | Dynamics of CD4+ T cells in HIV‐1 infection | |
| Kishimoto et al. | Usefulness of a model-based approach for estimating in vitro P-glycoprotein inhibition potency in a transcellular transport assay |